These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10560438)

  • 1. [Liver concentration of CPT-11, SN-38 and SN-38 GLU in intraperitoneal and intravenous administration of CPT-11].
    Maruyama M; Nagahama T; Yuasa Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1967-9. PubMed ID: 10560438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
    Natsui S; Maruyama M; Ochiai T; Hasegawa K; Takashima I; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2188-90. PubMed ID: 12484033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
    Maruyama M; Nagahama T; Ebuchi M; Yuasa Y
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1855-7. PubMed ID: 11086429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
    Maruyama M; Toukairin Y; Baba H; Kure N; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1505-7. PubMed ID: 11707965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis.
    Maruyama M; Nagahama T; Yuasa Y
    Anticancer Res; 1999; 19(5B):4187-91. PubMed ID: 10628373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
    Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1602-4. PubMed ID: 14619474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intraperitoneal administration of CPT-11 in rats--experimental study for pharmacokinetics].
    Nagahama T; Maruyama M; Goseki N
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1866-9. PubMed ID: 11086432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
    Ahn BJ; Choi MK; Park YS; Lee J; Park SH; Park JO; Lim HY; Kang WK; Ko JW; Yim DS
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1235-45. PubMed ID: 20827550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental study on CPT-11 intraperitoneal chemotherapy--metabolism of CPT-11 in malignant ascites].
    Maruyama M; Toukairin Y; Baba H; Yoshida T; Kure N; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1858-60. PubMed ID: 11086430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
    Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
    J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.
    Guichard S; Chatelut E; Lochon I; Bugat R; Mahjoubi M; Canal P
    Cancer Chemother Pharmacol; 1998; 42(2):165-70. PubMed ID: 9654118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental study on intraperitoneal and intravenous administration of anti-tumor agents for liver metastasis].
    Maruyama M; Nagahama T; Ebuchi M; Irie T; Yoshida T; Kure M
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1782-5. PubMed ID: 10560394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intraperitoneal irinotecan in a pig model.
    Turcotte S; Sideris L; Younan R; Drolet P; Dubé P
    J Surg Oncol; 2010 Jun; 101(7):637-42. PubMed ID: 20461774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic profile of Oncofid-S after intraperitoneal and intravenous administration in the rat.
    Tringali G; Bettella F; Greco MC; Campisi M; Renier D; Navarra P
    J Pharm Pharmacol; 2012 Mar; 64(3):360-5. PubMed ID: 22272720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.
    Hribaschek A; Kuhn R; Pross M; Meyer F; Fahlke J; Ridwelski K; Boltze C; Lippert H
    Surg Today; 2006; 36(1):57-62. PubMed ID: 16378195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
    Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
    Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antitumor activity of CPT-11 against rat Walker 256 carcinoma].
    Furuta T; Yokokura T; Mutai M
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2757-60. PubMed ID: 3415271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
    Takahashi T; Fujiwara Y; Sumiyoshi H; Isobe T; Yamaoka N; Yamakido M
    Cancer Chemother Pharmacol; 1997; 40(5):449-52. PubMed ID: 9272124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.